Experimental Factor Ontology (EFO) Information | |
Identifier | EFO_0007355 |
Description | A primary or metastatic malignant neoplasm involving the male reproductive system. Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma. [NCIT: C8561] | Trait category |
Cancer
|
Synonyms |
26 synonyms
|
Mapped term(s) |
10 mapped terms
|
Child trait(s) | 2 child traits |
Polygenic Score (PGS) ID | PGS Name | PGS Publication (PGP) ID | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants | PGS Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000030 | PrCa | PGP000019 Schumacher FR et al. Nat Genet (2018) | Prostate cancer | prostate carcinoma | 147 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000030/ScoringFiles/PGS000030.txt.gz |
PGS000044 | PrCa66 | PGP000031 Pashayan N et al. Br J Cancer (2015) | Prostate cancer | prostate carcinoma | 66 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000044/ScoringFiles/PGS000044.txt.gz |
PGS000049 | PRS103_PrCa | PGP000034 Lecarpentier J et al. J Clin Oncol (2017) | Prostate Cancer | prostate carcinoma | 103 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000049/ScoringFiles/PGS000049.txt.gz |
PGS000067 | PCa_PHS | PGP000047 Seibert TM et al. BMJ (2018) | Prostate cancer | prostate carcinoma | 54 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000067/ScoringFiles/PGS000067.txt.gz |
PGS000084 | CC_Prostate | PGP000050 Graff RE et al. bioRxiv (2020) Pre | Prostate cancer | prostate carcinoma | 161 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000084/ScoringFiles/PGS000084.txt.gz |
PGS000086 | CC_Testis | PGP000050 Graff RE et al. bioRxiv (2020) Pre | Testicular cancer | testicular carcinoma Testicular Germ Cell Tumor |
52 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000086/ScoringFiles/PGS000086.txt.gz |
PGS000160 | cGRS_Prostate | PGP000075 Shi Z et al. Cancer Med (2019) | Prostate cancer | prostate carcinoma | 79 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000160/ScoringFiles/PGS000160.txt.gz |
PGS000333 | PRS_PC | PGP000100 Mars N et al. Nat Med (2020) | Prostate cancer | prostate carcinoma | 6,606,785 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000333/ScoringFiles/PGS000333.txt.gz |
PGS000348 | PRS_PrCa | PGP000113 Black MH et al. Prostate (2020) | Prostate cancer | prostate carcinoma | 72 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000348/ScoringFiles/PGS000348.txt.gz |
PGS000565 | PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 21 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000565/ScoringFiles/PGS000565.txt.gz |
PGS000566 | PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,111,494 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000566/ScoringFiles/PGS000566.txt.gz |
PGS000567 | PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 78 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000567/ScoringFiles/PGS000567.txt.gz |
PGS000568 | PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,401 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000568/ScoringFiles/PGS000568.txt.gz |
PGS000569 | PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 49 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000569/ScoringFiles/PGS000569.txt.gz |
PGS000570 | PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,111,493 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000570/ScoringFiles/PGS000570.txt.gz |
PGS000571 | PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 100 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000571/ScoringFiles/PGS000571.txt.gz |
PGS000572 | PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,809 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000572/ScoringFiles/PGS000572.txt.gz |
PGS000573 | PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 31 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000573/ScoringFiles/PGS000573.txt.gz |
PGS000574 | PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,111,493 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000574/ScoringFiles/PGS000574.txt.gz |
PGS000575 | PRSWEB_PHECODE185_C61_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 47 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000575/ScoringFiles/PGS000575.txt.gz |
PGS000576 | PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 905 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000576/ScoringFiles/PGS000576.txt.gz |
PGS000577 | PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 117 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000577/ScoringFiles/PGS000577.txt.gz |
PGS000578 | PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 117 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000578/ScoringFiles/PGS000578.txt.gz |
PGS000579 | PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 122 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000579/ScoringFiles/PGS000579.txt.gz |
PGS000580 | PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 118 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000580/ScoringFiles/PGS000580.txt.gz |
PGS000581 | PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 377 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000581/ScoringFiles/PGS000581.txt.gz |
PGS000582 | PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 377 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000582/ScoringFiles/PGS000582.txt.gz |
PGS000583 | PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,119,311 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000583/ScoringFiles/PGS000583.txt.gz |
PGS000584 | PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,120,596 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000584/ScoringFiles/PGS000584.txt.gz |
PGS000585 | PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,301 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000585/ScoringFiles/PGS000585.txt.gz |
PGS000586 | PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,023 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000586/ScoringFiles/PGS000586.txt.gz |
PGS000587 | PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 26,418 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000587/ScoringFiles/PGS000587.txt.gz |
PGS000588 | PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 178,259 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000588/ScoringFiles/PGS000588.txt.gz |
PGS000589 | PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 42 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000589/ScoringFiles/PGS000589.txt.gz |
PGS000590 | PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,119,236 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000590/ScoringFiles/PGS000590.txt.gz |
PGS000591 | PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 80 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000591/ScoringFiles/PGS000591.txt.gz |
PGS000592 | PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of prostate | prostate carcinoma | 1,334 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000592/ScoringFiles/PGS000592.txt.gz |
PGS000593 | PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of other male genital organs | male reproductive organ cancer | 45 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000593/ScoringFiles/PGS000593.txt.gz |
PGS000594 | PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Cancer of other male genital organs | male reproductive organ cancer | 97 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000594/ScoringFiles/PGS000594.txt.gz |
PGS000595 | PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 9 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000595/ScoringFiles/PGS000595.txt.gz |
PGS000596 | PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 5 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000596/ScoringFiles/PGS000596.txt.gz |
PGS000597 | PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 771 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000597/ScoringFiles/PGS000597.txt.gz |
PGS000598 | PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 6 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000598/ScoringFiles/PGS000598.txt.gz |
PGS000599 | PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 31 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000599/ScoringFiles/PGS000599.txt.gz |
PGS000600 | PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 250 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000600/ScoringFiles/PGS000600.txt.gz |
PGS000601 | PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 40 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000601/ScoringFiles/PGS000601.txt.gz |
PGS000602 | PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 40 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000602/ScoringFiles/PGS000602.txt.gz |
PGS000603 | PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 22 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000603/ScoringFiles/PGS000603.txt.gz |
PGS000604 | PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Malignant neoplasm of testis | testicular carcinoma | 44 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000604/ScoringFiles/PGS000604.txt.gz |
PGS000662 | GRS.PCa.269 | PGP000122 Conti DV et al. Nat Genet (2021) | Prostate Cancer | prostate carcinoma | 269 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000662/ScoringFiles/PGS000662.txt.gz |
PGS000714 | PRS55_PC | PGP000130 Sipeky C et al. Sci Rep (2020) | Prostate cancer | prostate carcinoma | 55 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000714/ScoringFiles/PGS000714.txt.gz |
PGS000719 | PRS_Prostate | PGP000135 Jia G et al. JNCI Cancer Spectr (2020) | Prostate cancer | prostate carcinoma | 134 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000719/ScoringFiles/PGS000719.txt.gz |
PGS000733 | PHS46+African | PGP000139 Karunamuni RA et al. Int J Cancer (2020) | Prostate cancer | prostate carcinoma | 49 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000733/ScoringFiles/PGS000733.txt.gz |
PGS Performance Metric ID (PPM ID) |
Evaluated Score |
PGS Sample Set ID (PSS ID) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
PGS Classification Metrics | Other Metrics | Covariates Included in the Model | PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000061 | PGS000030 (PrCa) | PSS000041 | PGP000019 Schumacher FR et al. (2018) | Reported Trait: Prostate cancer | OR: 1.86 [1.83, 1.89] | — | — | Top 7 Genetic PCs, country | Samples were also part of the variant association |
PPM000204 | PGS000084 (CC_Prostate) | PSS000123 | PGP000050 Graff RE et al. (2020) Pre | Reported Trait: Prostate cancer | OR: 1.44 [1.41, 1.47] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB |
PPM000206 | PGS000086 (CC_Testis) | PSS000125 | PGP000050 Graff RE et al. (2020) Pre | Reported Trait: Testicular cancer | OR: 2.29 [2.13, 2.47] | — | — | Genotyping array, age, 10 PCs. | — |
PPM001674 | PGS000733 (PHS46+African) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) | Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 20% vs. bottom 20%): 4.42 [4.16, 4.67] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
PPM001257 | PGS000572 (PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.537 [1.433, 1.649] β: 0.43 (0.0358) |
AUROC: 0.616 [0.597, 0.636] | Nagelkerke's Pseudo-R²: 0.0418 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.59, 6.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608 |
PPM000987 | PGS000348 (PRS_PrCa) | PSS000502 | PGP000113 Black MH et al. (2020) | Reported Trait: Prostate cancer in men with a family history of prostate cancer | OR: 1.9 [1.53, 2.4] | — | — | Age | — |
PPM000986 | PGS000348 (PRS_PrCa) | PSS000501 | PGP000113 Black MH et al. (2020) | Reported Trait: Prostate cancer | — | AUROC: 0.64 | — | Age | — |
PPM000985 | PGS000348 (PRS_PrCa) | PSS000501 | PGP000113 Black MH et al. (2020) | Reported Trait: Prostate cancer | OR: 1.72 [1.59, 1.88] | AUROC: 0.64 [0.62, 0.66] | — | — | — |
PPM000183 | PGS000067 (PCa_PHS) | PSS000105 | PGP000047 Seibert TM et al. (2018) | Reported Trait: aggressive prostate cancer (age at onset) | — | — | — | — | z-test (p-value) < 1e-16 |
PPM000105 | PGS000044 (PrCa66) | PSS000069 | PGP000032 Pashayan N et al. (2015) Ext. | Reported Trait: aggressive prostate cancer (Gleason score ⩾7) | — | — | OR (above vs. below 50th percentile of PRS): 1.56 [1.15, 2.1] | — | — |
PPM000182 | PGS000067 (PCa_PHS) | PSS000105 | PGP000047 Seibert TM et al. (2018) | Reported Trait: aggressive prostate cancer | — | — | HR (Hazard ratio; top 2% vs. average risk): 2.9 [2.4, 3.4] | — | — |
PPM000184 | PGS000067 (PCa_PHS) | PSS000106 | PGP000047 Seibert TM et al. (2018) | Reported Trait: any prostate cancer | — | — | HR (Hazard ratio; top 2% vs. average risk): 2.5 [2.2, 2.8] | — | — |
PPM000185 | PGS000067 (PCa_PHS) | PSS000106 | PGP000047 Seibert TM et al. (2018) | Reported Trait: any prostate cancer (age at onset) | — | — | — | — | z-test (p-value) < 1e-16 |
PPM000187 | PGS000067 (PCa_PHS) | PSS000107 | PGP000047 Seibert TM et al. (2018) | Reported Trait: very aggressive prostate cancer (age at onset) | — | — | — | — | z-test (p-value) < 1e-11 |
PPM001675 | PGS000067 (PCa_PHS) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) Ext. | Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 2% vs. middle 40%): 2.1 [1.99, 2.21] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM001676 | PGS000733 (PHS46+African) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) | Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 2% vs. middle 40%): 3.67 [3.48, 3.87] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
PPM001677 | PGS000067 (PCa_PHS) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) Ext. | Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR bottom 20% vs. middle 40%): 0.65 [0.63, 0.67] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM001678 | PGS000733 (PHS46+African) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) | Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR bottom 20% vs. middle 40%): 0.51 [0.49, 0.52] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
PPM000393 | PGS000067 (PCa_PHS) | PSS000221 | PGP000058 Huynh-Le M et al. (2019) Ext. Pre | Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 2.4 [2.3, 2.6] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM000392 | PGS000067 (PCa_PHS) | PSS000222 | PGP000058 Huynh-Le M et al. (2019) Ext. Pre | Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.2 [4.8, 5.6] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM000391 | PGS000067 (PCa_PHS) | PSS000223 | PGP000058 Huynh-Le M et al. (2019) Ext. Pre | Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.6 [5.2, 6.0] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM000390 | PGS000067 (PCa_PHS) | PSS000220 | PGP000058 Huynh-Le M et al. (2019) Ext. Pre | Reported Trait: Age of aggressive prostate cancer onset | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.9 [5.5, 6.3] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM001679 | PGS000067 (PCa_PHS) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) Ext. | Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (HR top 20% vs. bottom 20%): 2.21 [2.04, 2.38] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM000394 | PGS000067 (PCa_PHS) | PSS000224 | PGP000058 Huynh-Le M et al. (2019) Ext. Pre | Reported Trait: Age of prostate cancer death | — | — | Hazard Ratio (HR; top 20% vs. rest): 5.7 [4.6, 7.0] | — | Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM001680 | PGS000733 (PHS46+African) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) | Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (top 20% vs. bottom 20%): 4.71 [4.38, 5.05] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
PPM001682 | PGS000733 (PHS46+African) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) | Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (top 2% vs. middle 40%): 3.89 [3.64, 4.13] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
PPM001683 | PGS000067 (PCa_PHS) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) Ext. | Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (bottom 20% vs. middle 40%): 0.7 [0.68, 0.73] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM001684 | PGS000733 (PHS46+African) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) | Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (bottom 20% vs. middle 40%): 0.5 [0.48, 0.52] | — | Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation |
PPM000104 | PGS000044 (PrCa66) | PSS000068 | PGP000031 Pashayan N et al. (2015) | Reported Trait: Elevated serum prostate-specific antigen (PSA) levels | — | — | OR (per 1-point increase in PRS): 1.23 [1.1, 1.37] | cancer stage, Gleason score | — |
PPM000123 | PGS000049 (PRS103_PrCa) | PSS000075 | PGP000034 Lecarpentier J et al. (2017) | Reported Trait: Prostate cancer in male carriers of BRCA1/2 mutations | OR: 1.56 [1.35, 1.81] | AUROC: 0.62 [0.58, 0.66] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
PPM000124 | PGS000049 (PRS103_PrCa) | PSS000077 | PGP000034 Lecarpentier J et al. (2017) | Reported Trait: Low prostate cancer aggressiveness (Gleason score < 7) | OR: 1.44 [1.1, 1.87] | — | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
PPM000125 | PGS000049 (PRS103_PrCa) | PSS000076 | PGP000034 Lecarpentier J et al. (2017) | Reported Trait: High prostate cancer aggressiveness (Gleason score ≥ 7) | OR: 1.67 [1.37, 2.04] | — | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | — |
PPM001681 | PGS000067 (PCa_PHS) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) Ext. | Reported Trait: Age at diagnosis of clinically significant prostate cancer | — | — | Hazard Ratio (top 2% vs. middle 40%): 1.91 [1.79, 2.04] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PPM000900 | PGS000333 (PRS_PC) | PSS000447 | PGP000100 Mars N et al. (2020) | Reported Trait: Incident prostate cancer | — | C-index: 0.866 | — | age, family history, history of benign prostate hyperplasia, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000895 | PGS000333 (PRS_PC) | PSS000447 | PGP000100 Mars N et al. (2020) | Reported Trait: Incident prostate cancer | — | C-index: 0.857 | — | age, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000186 | PGS000067 (PCa_PHS) | PSS000107 | PGP000047 Seibert TM et al. (2018) | Reported Trait: very aggressive prostate cancer | — | — | HR (Hazard ratio; top 2% vs. average risk): 3.0 [2.2, 4.0] | — | — |
PPM000491 | PGS000160 (cGRS_Prostate) | PSS000280 | PGP000075 Shi Z et al. (2019) | Reported Trait: Prostate cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.73 [1.38, 2.17] | — | — |
PPM000480 | PGS000160 (cGRS_Prostate) | PSS000280 | PGP000075 Shi Z et al. (2019) | Reported Trait: Prostate cancer | — | — | Mean realative risk: 1.3 [1.21, 1.38] Wilcoxon test (case vs. control) p-value: 2.07e-18 |
— | — |
PPM001273 | PGS000588 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608) | PSS000573 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 2.127 [2.043, 2.215] β: 0.755 (0.0206) |
AUROC: 0.699 [0.69, 0.71] | Nagelkerke's Pseudo-R²: 0.0943 Brier score: 0.0794 Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.85, 7.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608 |
PPM001258 | PGS000573 (PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.603 [1.495, 1.718] β: 0.472 (0.0355) |
AUROC: 0.622 [0.603, 0.641] | Nagelkerke's Pseudo-R²: 0.0497 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 2.93 [1.83, 4.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608 |
PPM001260 | PGS000575 (PRSWEB_PHECODE185_C61_PT_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.577 [1.47, 1.692] β: 0.456 (0.0359) |
AUROC: 0.619 [0.601, 0.637] | Nagelkerke's Pseudo-R²: 0.0456 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 3.1 [1.96, 4.92] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PT_MGI_20200608 |
PPM001264 | PGS000579 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.747 [1.626, 1.876] β: 0.558 (0.0364) |
AUROC: 0.646 [0.627, 0.664] | Nagelkerke's Pseudo-R²: 0.0675 Brier score: 0.147 Odds Ratio (OR, top 1% vs. Rest): 3.53 [2.26, 5.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608 |
PPM001267 | PGS000582 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608) | PSS000573 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.957 [1.882, 2.035] β: 0.671 (0.0201) |
AUROC: 0.681 [0.671, 0.692] | Nagelkerke's Pseudo-R²: 0.0776 Brier score: 0.0803 Odds Ratio (OR, top 1% vs. Rest): 4.85 [3.95, 5.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608 |
PPM001270 | PGS000585 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.907 [1.771, 2.053] β: 0.645 (0.0378) |
AUROC: 0.67 [0.652, 0.688] | Nagelkerke's Pseudo-R²: 0.0837 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 3.3 [2.06, 5.29] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608 |
PPM001276 | PGS000591 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.608 [1.498, 1.725] β: 0.475 (0.0359) |
AUROC: 0.627 [0.608, 0.645] | Nagelkerke's Pseudo-R²: 0.051 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 3.18 [2.01, 5.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608 |
PPM001279 | PGS000594 (PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608) | PSS000554 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of other male genital organs | OR: 1.227 [1.029, 1.464] β: 0.205 (0.0899) |
AUROC: 0.558 [0.506, 0.606] | Nagelkerke's Pseudo-R²: 0.00729 Brier score: 0.083 Odds Ratio (OR, top 1% vs. Rest): 1.04 [0.183, 5.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608 |
PPM001282 | PGS000597 (PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608) | PSS000553 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 1.667 [1.296, 2.143] β: 0.511 (0.128) |
AUROC: 0.656 [0.593, 0.717] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.084 Odds Ratio (OR, top 1% vs. Rest): 2.72 [0.568, 13.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608 |
PPM001285 | PGS000600 (PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608) | PSS000553 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 1.619 [1.267, 2.067] β: 0.482 (0.125) |
AUROC: 0.636 [0.565, 0.698] | Nagelkerke's Pseudo-R²: 0.046 Brier score: 0.0839 Odds Ratio (OR, top 1% vs. Rest): 6.35 [1.81, 22.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608 |
PPM001288 | PGS000603 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608) | PSS000553 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 1.625 [1.27, 2.079] β: 0.485 (0.126) |
AUROC: 0.625 [0.557, 0.693] | Nagelkerke's Pseudo-R²: 0.044 Brier score: 0.084 Odds Ratio (OR, top 1% vs. Rest): 6.05 [1.73, 21.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608 |
PPM000988 | PGS000348 (PRS_PrCa) | PSS000503 | PGP000113 Black MH et al. (2020) | Reported Trait: Prostate cancer in men with no family history of prostate cancer | OR: 1.65 [1.49, 1.84] | — | — | Age | — |
PPM001261 | PGS000576 (PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.489 [1.39, 1.596] β: 0.398 (0.0353) |
AUROC: 0.607 [0.589, 0.627] | Nagelkerke's Pseudo-R²: 0.0358 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 2.46 [1.5, 4.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608 |
PPM001250 | PGS000565 (PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.434 [1.336, 1.54] β: 0.361 (0.0363) |
AUROC: 0.596 [0.579, 0.615] | Nagelkerke's Pseudo-R²: 0.0271 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 2.39 [1.41, 4.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608 |
PPM001251 | PGS000566 (PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.393 [1.3, 1.493] β: 0.332 (0.0352) |
AUROC: 0.591 [0.573, 0.609] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.152 Odds Ratio (OR, top 1% vs. Rest): 2.85 [1.76, 4.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608 |
PPM001252 | PGS000567 (PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.505 [1.404, 1.613] β: 0.409 (0.0354) |
AUROC: 0.608 [0.59, 0.628] | Nagelkerke's Pseudo-R²: 0.0379 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 3.17 [1.98, 5.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608 |
PPM001253 | PGS000568 (PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.426 [1.332, 1.527] β: 0.355 (0.035) |
AUROC: 0.595 [0.577, 0.614] | Nagelkerke's Pseudo-R²: 0.0281 Brier score: 0.151 Odds Ratio (OR, top 1% vs. Rest): 1.53 [0.88, 2.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608 |
PPM001254 | PGS000569 (PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.643 [1.531, 1.763] β: 0.496 (0.036) |
AUROC: 0.63 [0.613, 0.648] | Nagelkerke's Pseudo-R²: 0.0543 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 2.86 [1.79, 4.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608 |
PPM001256 | PGS000571 (PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.67 [1.555, 1.793] β: 0.513 (0.0363) |
AUROC: 0.634 [0.617, 0.653] | Nagelkerke's Pseudo-R²: 0.0583 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 2.96 [1.85, 4.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608 |
PPM001263 | PGS000578 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608) | PSS000573 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.746 [1.681, 1.813] β: 0.557 (0.0192) |
AUROC: 0.653 [0.642, 0.662] | Nagelkerke's Pseudo-R²: 0.0565 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.31 [3.48, 5.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608 |
PPM001265 | PGS000580 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608) | PSS000573 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.748 [1.684, 1.815] β: 0.559 (0.0192) |
AUROC: 0.653 [0.643, 0.663] | Nagelkerke's Pseudo-R²: 0.0568 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 4.34 [3.51, 5.37] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608 |
PPM001266 | PGS000581 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.79 [1.665, 1.925] β: 0.582 (0.0371) |
AUROC: 0.651 [0.634, 0.669] | Nagelkerke's Pseudo-R²: 0.071 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 4.44 [2.87, 6.87] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608 |
PPM001268 | PGS000583 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.929 [1.79, 2.078] β: 0.657 (0.038) |
AUROC: 0.668 [0.651, 0.687] | Nagelkerke's Pseudo-R²: 0.0874 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.28, 5.72] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608 |
PPM001269 | PGS000584 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608) | PSS000573 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 2.173 [2.087, 2.263] β: 0.776 (0.0206) |
AUROC: 0.705 [0.695, 0.715] | Nagelkerke's Pseudo-R²: 0.1 Brier score: 0.0791 Odds Ratio (OR, top 1% vs. Rest): 5.58 [4.58, 6.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608 |
PPM001271 | PGS000586 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608) | PSS000573 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 2.018 [1.94, 2.1] β: 0.702 (0.0203) |
AUROC: 0.687 [0.678, 0.698] | Nagelkerke's Pseudo-R²: 0.0837 Brier score: 0.0799 Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.84, 7.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608 |
PPM001272 | PGS000587 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.906 [1.771, 2.051] β: 0.645 (0.0375) |
AUROC: 0.665 [0.647, 0.684] | Nagelkerke's Pseudo-R²: 0.0861 Brier score: 0.145 Odds Ratio (OR, top 1% vs. Rest): 4.92 [3.21, 7.55] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608 |
PPM001274 | PGS000589 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.63 [1.52, 1.748] β: 0.489 (0.0356) |
AUROC: 0.63 [0.612, 0.648] | Nagelkerke's Pseudo-R²: 0.0532 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 3.14 [1.99, 4.96] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608 |
PPM001275 | PGS000590 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.516 [1.415, 1.624] β: 0.416 (0.0353) |
AUROC: 0.614 [0.595, 0.633] | Nagelkerke's Pseudo-R²: 0.0395 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.42, 3.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608 |
PPM001277 | PGS000592 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.537 [1.433, 1.648] β: 0.43 (0.0357) |
AUROC: 0.616 [0.598, 0.635] | Nagelkerke's Pseudo-R²: 0.0408 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.55, 4.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608 |
PPM001278 | PGS000593 (PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608) | PSS000554 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of other male genital organs | OR: 1.193 [1.002, 1.419] β: 0.176 (0.0887) |
AUROC: 0.551 [0.5, 0.6] | Nagelkerke's Pseudo-R²: 0.00553 Brier score: 0.0831 Odds Ratio (OR, top 1% vs. Rest): 1.01 [0.177, 5.76] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608 |
PPM001280 | PGS000595 (PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608) | PSS000553 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 1.713 [1.33, 2.206] β: 0.538 (0.129) |
AUROC: 0.658 [0.594, 0.719] | Nagelkerke's Pseudo-R²: 0.0543 Brier score: 0.0838 Odds Ratio (OR, top 1% vs. Rest): 2.64 [0.535, 13.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608 |
PPM001281 | PGS000596 (PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608) | PSS000553 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 1.68 [1.28, 2.206] β: 0.519 (0.139) |
AUROC: 0.649 [0.586, 0.714] | Nagelkerke's Pseudo-R²: 0.0475 Brier score: 0.0841 Odds Ratio (OR, top 1% vs. Rest): 3.49 [0.816, 14.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608 |
PPM001283 | PGS000598 (PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608) | PSS000553 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 1.639 [1.263, 2.126] β: 0.494 (0.133) |
AUROC: 0.648 [0.581, 0.712] | Nagelkerke's Pseudo-R²: 0.0447 Brier score: 0.0841 Odds Ratio (OR, top 1% vs. Rest): 3.85 [0.942, 15.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608 |
PPM001284 | PGS000599 (PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608) | PSS000553 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 1.628 [1.281, 2.069] β: 0.487 (0.122) |
AUROC: 0.637 [0.568, 0.703] | Nagelkerke's Pseudo-R²: 0.0473 Brier score: 0.0844 Odds Ratio (OR, top 1% vs. Rest): 4.35 [1.08, 17.5] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608 |
PPM001286 | PGS000601 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608) | PSS000553 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 1.438 [1.132, 1.827] β: 0.363 (0.122) |
AUROC: 0.598 [0.526, 0.672] | Nagelkerke's Pseudo-R²: 0.0258 Brier score: 0.085 |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608 |
PPM001287 | PGS000602 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608) | PSS000574 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 2.055 [1.692, 2.496] β: 0.72 (0.0993) |
AUROC: 0.698 [0.656, 0.74] | Nagelkerke's Pseudo-R²: 0.0839 Brier score: 0.0795 Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608 |
PPM001289 | PGS000604 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608) | PSS000574 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Malignant neoplasm of testis | OR: 2.106 [1.729, 2.565] β: 0.745 (0.101) |
AUROC: 0.703 [0.659, 0.745] | Brier score: 0.0793 Nagelkerke's Pseudo-R²: 0.0882 Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608 |
PPM001259 | PGS000574 (PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.506 [1.406, 1.614] β: 0.41 (0.0352) |
AUROC: 0.612 [0.593, 0.63] | Nagelkerke's Pseudo-R²: 0.039 Brier score: 0.15 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.24, 3.52] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608 |
PPM001255 | PGS000570 (PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.572 [1.465, 1.687] β: 0.452 (0.0359) |
AUROC: 0.622 [0.604, 0.639] | Nagelkerke's Pseudo-R²: 0.0453 Brier score: 0.149 Odds Ratio (OR, top 1% vs. Rest): 2.66 [1.63, 4.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608 |
PPM001262 | PGS000577 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608) | PSS000552 | PGP000118 Fritsche LG et al. (2020) | Reported Trait: Cancer of prostate | OR: 1.756 [1.634, 1.886] β: 0.563 (0.0366) |
AUROC: 0.646 [0.627, 0.665] | Nagelkerke's Pseudo-R²: 0.0678 Brier score: 0.147 Odds Ratio (OR, top 1% vs. Rest): 3.57 [2.29, 5.57] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608 |
PPM001365 | PGS000662 (GRS.PCa.269) | PSS000596 | PGP000122 Conti DV et al. (2021) | Reported Trait: Prostate Cancer | — | AUROC: 0.833 | Odds ratio (OR, top 10% versus 40-60% GRS): 4.17 Overall Net Reclassification Index (NRI [%]): 59.4 |
Age, 10 PCs | — |
PPM001366 | PGS000662 (GRS.PCa.269) | PSS000595 | PGP000122 Conti DV et al. (2021) | Reported Trait: Prostate Cancer | — | AUROC: 0.679 | Odds ratio (OR, top 10% versus 40-60% GRS): 3.53 | Age, 10 PCs, study | — |
PPM000890 | PGS000333 (PRS_PC) | PSS000446 | PGP000100 Mars N et al. (2020) | Reported Trait: Prostate cancer (incident and prevalent cases) | HR: 1.83 [1.78, 1.9] | — | — | genotyping array/batch, 10 ancestry PCs | — |
PPM001644 | PGS000719 (PRS_Prostate) | PSS000860 | PGP000135 Jia G et al. (2020) | Reported Trait: Incident prostate cancer | — | AUROC: 0.662 [0.655, 0.67] | — | Genotyping array | — |
PPM001645 | PGS000719 (PRS_Prostate) | PSS000860 | PGP000135 Jia G et al. (2020) | Reported Trait: Incident prostate cancer | — | AUROC: 0.669 [0.661, 0.676] | — | family history of cancer (in first-degree relatives), genotyping array | — |
PPM001624 | PGS000714 (PRS55_PC) | PSS000840 | PGP000130 Sipeky C et al. (2020) | Reported Trait: Prostate cancer | OR: 2.13 [1.9, 2.39] | AUROC: 0.618 [0.6, 0.63] | — | — | — |
PPM001625 | PGS000714 (PRS55_PC) | PSS000841 | PGP000130 Sipeky C et al. (2020) | Reported Trait: Prostate cancer (clinical cases) | OR: 2.18 [1.93, 2.45] | AUROC: 0.622 [0.61, 0.64] | — | — | — |
PPM001626 | PGS000714 (PRS55_PC) | PSS000843 | PGP000130 Sipeky C et al. (2020) | Reported Trait: Prostate cancer (screening trial detected) | OR: 1.92 [1.56, 2.37] | AUROC: 0.597 [0.57, 0.63] | — | — | — |
PPM001627 | PGS000714 (PRS55_PC) | PSS000842 | PGP000130 Sipeky C et al. (2020) | Reported Trait: Metastatic prostate cancer | OR: 1.47 | AUROC: 0.549 | — | — | — |
PPM001673 | PGS000067 (PCa_PHS) | PSS000874 | PGP000139 Karunamuni RA et al. (2020) Ext. | Reported Trait: Age at diagnosis of any prostate cancer | — | — | Hazard Ratio (HR top 20% vs. bottom 20%): 2.47 [2.32, 2.62] | — | 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94). |
PGS Sample Set ID (PSS ID) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000076 | — | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
PSS000077 | — | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |
PSS000554 | PheCode:187; ICD9CM:186.0, 186.9, 187.1, 187.2, 187.3, 187.4, 187.5, 187.6, 187.7, 187.8, 187.9, 233.5, 233.6, 236.4, 236.5, 236.6, V10.45, V10.47, V10.48, V10.49; ICD10CM:C60, C60.0, C60.1, C60.2, C60.8, C60.9, C62, C62.0, C62.00, C62.01, C62.02, C62.1, C62.10, C62.11, C62.12, C62.9, C62.90, C62.91, C62.92, C63, C63.0, C63.00, C63.01, C63.02, C63.1, C63.10, C63.11, C63.12, C63.2, C63.7, C63.8, C63.9, D07.4, D07.6, D07.60, D07.61, D07.69, D40, D40.0, D40.1, D40.10, D40.11, D40.12, D40.8, D40.9 | — | [
|
— | European | — | MGI | — |
PSS000123 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28010 | — | [ ,
100.0 % Male samples |
— | European | — | GERA, UKB | — |
PSS000553 | PheCode:187.2; ICD9CM:186.0, 186.9, V10.47; ICD10CM:C62, C62.0, C62.00, C62.01, C62.02, C62.1, C62.10, C62.11, C62.12, C62.9, C62.90, C62.91, C62.92 | — | [
|
— | European | — | MGI | — |
PSS000125 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28020 | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
PSS000502 | Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. | — | [ ,
100.0 % Male samples |
— | European (USA, NR) |
— | AG, JHH | — |
PSS000501 | Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. NSGI controls had a minimum of 1 year clincal history available in the EHR and were exlucded if any ICD9/10 diagnosis of cancer was present at any time in the EHR. Men who tested positive for RPVs in any prostate cancer susceptibility gene were exlcuded from further analysis. | — | [ ,
100.0 % Male samples |
— | European (USA, NR) |
— | AG, JHH, NSGHI | — |
PSS000503 | Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. | — | [ ,
100.0 % Male samples |
— | European (USA, NR) |
— | AG, JHH | — |
PSS000041 | For each cohort core data on disease status, age at diagnosis (age at observation or questionnaire for controls), family history of PrCa, and clinical factors for cases (for example, PSA at diagnosis and Gleason score) was extracted | — | [ ,
100.0 % Male samples |
— | European | — | 43 cohorts
|
These samples (OncoArray) were also used in the GWAS meta-analysis |
PSS000573 | PheCode:185; ICD9:185, 233.4; ICD10:C61, D07.5 | — | [
|
— | European | — | UKB | — |
PSS000574 | PheCode:187.2; ICD9:186, 186.0, 186.9; ICD10:C62.0, C62.1, C62.9 | — | [
|
— | European | — | UKB | — |
PSS000840 | Cases: clinically diagnosed or screen-detected prostate cancer. Controls: free of cancer | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC, PHD | — |
PSS000841 | Cases: clinically diagnosed with prostate cancer. Controls: free of cancer. | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC, PHD | — |
PSS000842 | — | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC, PHD | — |
PSS000843 | Cases: screen-detected prostate cancer. Controls: free of cancer. | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinRSPC | — |
PSS000220 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR | Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
PSS000221 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | African unspecified | Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
PSS000222 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | Asian unspecified | Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
PSS000223 | Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases | — | [ ,
100.0 % Male samples |
— | European | Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
PSS000224 | Age at death due to prostate cancer. | — | [ ,
100.0 % Male samples |
Mean = 70.0 years Iqr = [63.0, 76.0] years |
European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR | Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) | OncoArray_Prostate | List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1 |
PSS000595 | — | — | [ ,
100.0 % Male samples |
— | African unspecified | — | CAUG | — |
PSS000596 | — | — | [ ,
100.0 % Male samples |
— | European | — | UKB | — |
PSS000860 | Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Prostate=(ICD-9 = 185 or ICD-10 = C61) | Median = 5.8 years | [ ,
46.5 % Male samples |
— | European | — | UKB | — |
PSS000280 | Primary tumor samples from TCGA | — | [ ,
100.0 % Male samples |
Mean = 62.0 years Sd = 7.0 years |
European | — | TCGA | — |
PSS000280 | — | — | [ ,
100.0 % Male samples |
— | European | — | eMERGE | — |
PSS000105 | Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. | — | 4,828 individuals, 100.0 % Male samples |
Mean = 59.0 years Iqr = [55.0, 63.0] years |
European | — | ProtecT | — |
PSS000105 | Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of aggressive prostate cancer (defined as any of Gleason score ≥7, stage T3-T4, PSA concentration ≥10 ng/mL, nodal metastasis, or distant metastasis) | — | [ ,
100.0 % Male samples |
Mean = 64.3 years Iqr = [60.2, 67.5] years |
European | — | ProtecT | — |
PSS000106 | Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. | — | 4,828 individuals, 100.0 % Male samples |
Mean = 59.0 years Iqr = [55.0, 63.0] years |
European | — | ProtecT | — |
PSS000106 | Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of prostate cancer. | — | [ ,
100.0 % Male samples |
Mean = 63.4 years Iqr = [59.0, 67.5] years |
European | — | ProtecT | — |
PSS000107 | Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. | — | 4,828 individuals, 100.0 % Male samples |
Mean = 59.0 years Iqr = [55.0, 63.0] years |
European | — | ProtecT | — |
PSS000107 | Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of very aggressive prostate cancer (defined as any of Gleason score ≥8, stage T3-4, positive nodes, or distant metastases) | — | [ ,
100.0 % Male samples |
— | European | — | ProtecT | — |
PSS000874 | Clinically significant cancer were any of: Gleason score ≥ 7, stage T3-T4, PSA concentration ≥ 10 ng/mL, pelvic lymph nodal metastasis or distant metastasis. | — | [ ,
100.0 % Male samples |
— | African unspecified | — | 18 cohorts
|
PRACTICAL consortium |
PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | ProtecT | — |
PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 60.0] years | European | — | UKGPCS | — |
PSS000069 | Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7. | Median = 13.0 years | [ ,
100.0 % Male samples |
Range = [55.0, 71.0] years | European (Finnish) |
— | ERSPC | — |
PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | SEARCH | — |
PSS000446 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |
PSS000447 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [
|
— | European (Finnish) |
— | FinnGen | — |
PSS000552 | PheCode:185; ICD9CM:185, 233.4, V10.46; ICD10CM:C61, D07.5 | — | [
|
— | European | — | MGI | — |
PSS000075 | Breast and prostate cancer cases were defined on the basis of age at diagnosis, whichever occurred first. If breast and prostate cancer occurred at the same time, individuals were treated as patients with breast cancer. | — | [ ,
100.0 % Male samples |
— | European | Self-reported European ancestry | 37 cohorts
|
— |